Person who experienced the adverse event (patient)
Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
79116145 | 7911614 | 5 | F | 20091210 | 20160912 | 20110422 | 20160915 | EXP | US-JNJFOC-20110409781 | JANSSEN | 38.88 | YR | A | M | Y | 99.11000 | KG | 20160915 | MD | US | US |
Drug(s) used by person
Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
79116145 | 7911614 | 1 | PS | STELARA | USTEKINUMAB | 1 | Subcutaneous | Y | N | 125261 | 90 | MG | SOLUTION FOR INJECTION | ||||||
79116145 | 7911614 | 2 | SS | REMICADE | INFLIXIMAB | 1 | Intravenous (not otherwise specified) | Y | N | 9GM57011P1 | 103772 | 5 | MG/KG | LYOPHILIZED POWDER | |||||
79116145 | 7911614 | 3 | C | CORTICOSTEROIDS | CORTICOSTEROID NOS | 1 | U | 0 |
Indications of drugs used
Event ID | CASEID | INDI DRUG SEQ | INDI PT |
---|---|---|---|
79116145 | 7911614 | 1 | Psoriasis |
79116145 | 7911614 | 2 | Psoriatic arthropathy |
79116145 | 7911614 | 3 | Product used for unknown indication |
Outcome of event
Event ID | CASEID | OUTC COD |
---|---|---|
79116145 | 7911614 | OT |
Reactions reported
Event ID | CASEID | DRUG REC ACT | PT |
---|---|---|---|
79116145 | 7911614 | Psoriatic arthropathy |
Reporting Sources (this data is often not reported and may therefore be missing here)
no results found |
Therapies reported
Event ID | CASEID | DSG DRUG SEQ | START DT | END DT | DUR | DUR COD |
---|---|---|---|---|---|---|
79116145 | 7911614 | 1 | 20091210 | 0 | ||
79116145 | 7911614 | 2 | 200511 | 20090929 | 0 |